


How similar is this cluster to the other clusters?

Genes in the cluster along with the pathways as annotated by experts


Expert Annotation		
Treatment	Pathway	Regulation Type
MAPKAP1.WT	Canonical TOR	Activator
SGK3.WT.2	Canonical TOR	Activator
CSNK1A1.WT.3	Canonical WNT	Inhibitor




Top 5 genes negatively correlated to the cluster

Expert Annotation			Mean Correlation	Standard Deviation
Treatment	Pathway	Regulation Type		
PRKACA.WT.2	Canonical PKA	Activator	-0.60	0.02
PRKACA.WT.1	Canonical PKA	Activator	-0.51	0.05
CXXC4.WT	WNT	Inhibitor	-0.50	0.12
STK3.WT.2	Canonical Hippo	Activator	-0.49	0.26
PIK3CB.WT.2	Canonical PI3K/AKT	Activator	-0.46	0.09

What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?







Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)

CSNK1A1.WT.3




MAPKAP1.WT

SGK3.WT.2

RNA



Mito





Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster	Chemical structure	Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.52)	Mean \pm standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes	Mean compound rank when scored against genes in cluster using L1000 profiling \pm standard deviation; Tables contain data for individual genes	How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)	Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples	Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster	Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized
BRD-K05950645-001-07-2 MLS000536739 SMR000155669 AC1LGWR5 BDBM48497 HMS1485K04 HMS2379O21 ID11_022358 F1386-0259 T0500-8534 PubChem CID : 828338		NA (in 1 replicates)	0.56 ± 0.07 Treatment : Score CSNK1A1.WT.3 0.50 MAPKAP1.WT.1 0.05 SGK3.WT.2 -0.04	NA				Total number of assays tested in: 701. Active in the following assays: <ul style="list-style-type: none">HTS for Estrogen Receptor-beta Coactivator Binding Inhibitors (AID 633)Screening for Modulators of Post-Golgi Transport, Control Strain (AID 738)CYP2C9 Assay (AID 777)CYP2C19 Assay (AID 778)Inhibitors of Plasmodium falciparum M17-Family Leucine Aminopeptidase (M17LAP) (AID 1619)Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity (AID 2221)Fluorescence Cell-Free Homogeneous Counter Screen to Identify Inhibitors of GFP Chromophore Formation (AID 434968)Fluorescence Cell-Free Homogeneous Dose Retest to Identify Inhibitors of RecA-Intein Splicing Activity (AID 435010)Fluorescence Cell-Free Homogeneous Secondary Screen to Identify Inhibitors of DnaB-Intein Splicing Activity (AID 449749)Fluorescence Cell-Free Homogeneous Secondary Screen to Identify Non-Covalent Inhibitors of RecA-Intein Splicing Activity (AID 449750)

O=C1C(Cl)=NC(C2=CC=CC=C2)=N1

Treatment	Score
CSNK1A1.WT.3	0.45
MAPKAP1.WT	0.45
SGK3.WT.2	0.69

Category	Mean Collection of Grants (in % of the population)
1	-0.05
2	0.50
3	-0.15
4	0.15
5	-0.35
6	0.25
7	-0.25
8	0.50
9	-0.25
10	0.35
11	-0.05
12	-0.45
13	0.15
14	0.25





Total number of assays tested in: 791. Active in the following assays:

- Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity (AID 524)
- Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (RhoK2) (AID 604)
- CYP2C9 Assay (AID 777)
- CYP2C19 Assay (AID 778)
- qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase (AID 1631)
- qHTS Assay for Inhibitors of JMJD2A-Tudor Domain (AID 50439)
- qHTS for Inhibitors of FLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 725054)
- qRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17. (AID 720648)

Treatment	Score
CSNK1A1.WT.3	0.46
MAPKAP1.WT	0.42
SGK3.WT.2	0.61

A bar chart showing the Mean Correlation of growth in the subset of the population for 12 different groups. The y-axis ranges from -0.6 to 0.6. The bars represent different groups, with some positive and some negative correlations.

Group	Mean Correlation
1	0.00
2	0.42
3	-0.05
4	0.12
5	-0.28
6	0.25
7	0.48
8	-0.15
9	0.38
10	0.00
11	-0.32
12	-0.08
13	0.05
14	0.15
15	0.00





Total number of assays tested in: 791. Active in the following assays:


- Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity (AID 524)
- Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (RhoK2) (AID 604)
- CYP2C9 Assay (AID 777)
- CYP2C19 Assay (AID 778)
- qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase (AID 1631)
- qHTS Assay for Inhibitors of JMJD2A-Tudor Domain (AID 50439)
- qHTS for Inhibitors of FLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 725054)
- qRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17. (AID 720648)

Treatment	Score
CSNK1A1.WT.3	0.56
MAPKAP1.WT	0.34
SGK3.WT.2	0.56

Category	Mean Coefficient of growth
1	0.05
2	0.10
3	-0.15
4	-0.15
5	0.00
6	-0.05
7	0.45
8	-0.35
9	0.25
10	-0.25
11	-0.05
12	0.00
13	0.05
14	0.15
15	0.15






BRD-K81339550-001-06-0
T0511-3166
ZINC03223178
AC1M64FM
MLS001006094
HMS2706H03
ZINC3223178
SMR000349131
5354-48-3
PubChem CID : 2341607



NA (in 1 replicates)

Treatment	Score
CSNK1A1.WT.3	0.48
MAPKAP1.WT	0.41
SGK3.WT.2	0.55


NA



Total number of assays tested in: 626. Active in the following assays:

- Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90) (AID 1789)
- MLPCN Alpha-Synuclein 5'UTR - 5'UTR binding - activators (AID 1814)
- Luminescence-based confirmation biochemical high throughput screening assay for inhibitors of the Heat Shock Protein 90 (HSP90) (AID 1846)
- Luminescence-based counterscreen assay for HSP90 inhibitors: biochemical high throughput screening assay to identify inhibitors of native inhibitors (AID 1847)
- Aqueous Solubility from MLMSR Stock Solutions (AID)
- Luminescence Cell-Based Dose Response HTS to Identify Activators of 5'UTR Stem-Loop Driven Prion Protein mRNA Translation in H. Neuroglioblastoma Cells (AID 1999)
- Luminescence Cell-Based Dose Response HTS to Identify Activators of Luciferase Translation or Activity in H4 Neuroglioblastoma Cells (AID 2002)
- Luminescence Cell-Based Dose Confirmation HTS to Identify Activators of 5'UTR Stem-Loop Driven Alpha-Synuclein mRNA Translation in H4 Neuroglioblastoma Cells (AID 2003)
- Cycloheximide Counterscreens for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
- A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)
- qHTS Assay for RaI9 Promoter Activators (AID 485297)
- qHTS screen for small molecules that increase glucosylamine in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELGI (AID 504466)
- qHTS profiling assay for purified luciferase in inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)
- qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression (AID 624202)




BRD-K58393684-001-05-7
MLS000062598
GNF-PF-2876
SIRM000071624
AC1M2NL4
Ambcb6067889
Ambcb7126688
CHEMBL601578
BDBM42950
HMS2383K20
ZINC06492245
ZINC87711567
PubChem CID : 2174924



NA (in 1 replicates)


Treatment	Score
CSNK1A1.WT.3	0.34
MAPKAP1.WT	0.53
SGK3.WT.2	0.56

NA



- Total number of assays tested in: 810. Active in the following assays:
 - HTS for BAP1 Enzyme inhibitors (AID 436)
 - Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen (AID 628)
 - Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Confirmation Screen (AID 677)
 - Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) (AID 1032)
 - Measurement of Tri-FRET directed format assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) (AID 1049)
 - A small molecule screen for inhibitors of the Phospho regulator in *Salmonella typhi* (AID 1850)
 - A screen for inhibitors of the Phospho regulator in *Salmonella typhi* using a modified counter screen (AID 1985)
 - A cytotoxicity screen for small molecule inhibitors of the Phospho regulator in *Salmonella typhi* identified in the primary screen (AID 2252)
 - A counter screen for small molecule screen for inhibitors of the Phospho regulator in *Salmonella typhi* (AID 2329)
 - NOVARTIS: Inhibition of Phosphoinositide dependent 3DT (drug-resistant) proliferation in erythrocyte-based infection assay (AID 49703)
 - NOVARTIS: Inhibition of Phosphoinositide dependent W2 (drug-resistant) proliferation in erythrocyte-based infection assay (AID 49704)
 - Phenotypic HTS multiplex for antifungal efflux pump inhibitors (AID 485275)
 - Primary qHTS for delayed death inhibitors of the malarial parasite plasmod, 48h incubation (AID 504832)
 - Confirmation screen for delayed death in inhibitors of the malarial parasite plasmod, 96h incubation (AID 504848)
 - Confirmation screen for delayed death in inhibitors of the malarial parasite plasmod, 48h incubation (AID 504850)
 - qHTS for Inhibitors of human tyrosine-DNA topoisomerase II (TDPI): qHTS in cells in absence of CPT (AID 686978)
 - qHTS for Inhibitors of human tyrosine-DNA topoisomerase II (TDPI): qHTS in cells in presence of CPT (AID 686979)
 - Confirmed allosteric antagonists of M1 Muscarinic receptor (AID 1063187)




BRD-A86682819-001-05-9
SMR000132149
MLS000521741
MLS002586576
HMS2504L07
PubChem CID : 9550295



NA (in 1 replicates)


Treatment	Score
CSNK1A1.WT.3	0.40
MAPKAP1.WT	0.54
SGK3.WT.2	0.44

NA



Total number of assays tested in: 671




BRD-K26720351-001-04-5
F0324-0011
SMR000235950
AC1N2WPT
MLS000722326
HMS594A03
HMS2562D13
ZINC754028
ZINC00754028
EU-0037277
PubChem CID : 4078248



NA (in 1 replicates)



Treatment	Score
CNNK1A1.WT.3	0.56
MAPKAP1.WT	0.33
SGK3.WT.2	0.48

NA



Total number of assays tested in: 585. Active in the following assays:

- High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta-Catenin Expression (AID 818)
- High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor (AID 827)
- hHTS of McI-1/Bid interaction inhibitors (AID 1021)
- High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta-Catenin Expression - Dose Response (AID 1045)
- High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor - Dose Response (AID 1047)
- Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation (AID 1321)
- HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress (AID 2732)
- Primary qHTS for delayed death inhibitors of the malarial parasite plasmod, 96 hour incubation (AID 504834)
- HTS to identify compounds that promote myeloid differentiation with MLPNC compound set (AID 624256)
- A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (AID 624296)
- A quantitative high throughput screen for small molecules that induce DNA re-replication in SW 620 colon adenocarcinoma cells. (AID 624297)
- qHTS for induction of synaptic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line (AID 686970)
- qHTS for induction of synaptic lethality in tumor cells producing 2HG: qHTS for the HT-1080-DHDK cell line (AID 686971)

BRD-K02630067-001-01-5 PubChem CID : 54619891		0.66 (in 4 replicates)	0.45 ± 0.07 Treatment Score ----- CNSK1A1.WT.4 0.42 MAPKAP1.WT 0.46 SGK3.WT.2 0.43	NA				Total number of assays tested in: 37.
BRD-K11696795-001-01-4 PubChem CID : 54634120		0.65 (in 3 replicates)	0.44 ± 0.14 Treatment Score ----- CNSK1A1.WT.4 0.43 MAPKAP1.WT 0.48 SGK3.WT.2 0.60 0.446 ± 0.275 Treatment Score ----- CNSK1A1.WT.4 0.38 MAPKAP1.WT 0.41 SGK3.WT.2 0.26	NA				Total number of assays tested in: 37.
BRD-K62820230-001-01-1 PubChem CID : 54649258		0.62 (in 2 replicates)	-0.45 ± 0.11 Treatment Score ----- CNSK1A1.WT.4 0.42 MAPKAP1.WT 0.44 SGK3.WT.2 -0.43 0.937 ± 0.077 Treatment Score ----- CNSK1A1.WT.4 0.48 MAPKAP1.WT 0.49 SGK3.WT.2 0.91	NA				Total number of assays tested in: 38.
BRD-K09155468-001-01-1 PubChem CID : 54641246		NA (in 1 replicates)	-0.43 ± 0.08 Treatment Score ----- CNSK1A1.WT.4 -0.41 MAPKAP1.WT -0.41 SGK3.WT.2 -0.40	NA				Total number of assays tested in: 37.
BRD-K62613235-001-04-9 SMR000627657 MLS001123513 MLS003880826 HMS2253J10 ZINC9441656 PubChem CID : 22552136		NA (in 1 replicates)	-0.42 ± 0.17 Treatment Score ----- CNSK1A1.WT.4 -0.23 MAPKAP1.WT -0.45 SGK3.WT.2 -0.48	NA				Total number of assays tested in: 486. Active in the following assays: ● qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)
BRD-K14997413-001-01-5 PubChem CID : 44494941		0.91 (in 2 replicates)	-0.42 ± 0.15 Treatment Score ----- CNSK1A1.WT.4 -0.40 MAPKAP1.WT -0.28 SGK3.WT.2 -0.48 0.352 ± 0.103 Treatment Score ----- CNSK1A1.WT.4 0.28 MAPKAP1.WT 0.79 SGK3.WT.2 0.48	NA				Total number of assays tested in: 33.
BRD-K76431854-001-01-6 PubChem CID : 56835376		0.78 (in 3 replicates)	-0.42 ± 0.18 Treatment Score ----- CNSK1A1.WT.4 -0.61 MAPKAP1.WT -0.26 SGK3.WT.2 -0.38 0.250 ± 0.042 Treatment Score ----- CNSK1A1.WT.4 0.28 MAPKAP1.WT 0.26 SGK3.WT.2 0.25	NA				Total number of assays tested in: 33.